- Real-world effectiveness of pembrolizumab as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma: the ARON-2 study2023 | Faculty of Medicine in Pilsen
- Bone targeting agents, but not radiation therapy, improves survival in patients with bone metastases from advanced urothelial carcinoma receiving pembrolizumab: results from the ARON-2 study2023 | Faculty of Medicine in Pilsen
- Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: data from the ARON-2 retrospective study2023 | Faculty of Medicine in Pilsen, Faculty of Medicine in Hradec Králové